Neoantigenics, a Charlottesville, VA-based biotech company that is developing a targeted treatment for cancer, raised a funding round with the CIT GAP Funds.
The amount of the funding was not disclosed.
The company intends to use the capital to advance its antibody drug agent in pre-clinical studies.
Established in July 2012 as a University of Virginia spin-out to advance the research and development of novel research findings of Dr. John Herr on oocyte proteomics, Neoantigenics holds an exclusive license from U.Va. Licensing and Ventures Group to the intellectual property of Herr on oocyte-associated biomarkers in the cancer field.
Led by CEO Dr. Brian Pollok, the company is actively advancing both monoclonal antibody agents to these biomarkers, as well as molecular diagnostic assays for precision, personalized medicine. Earlier this year, it announced a partnership and investment from Pfizer, Inc.
FinSMEs
12/04/2014